Immunofunctional carrier, methods of uses, and composition matters as an antitumor immunotherapy

Abstract

The present disclosure generally relates to a composition matter and a method for cancer treatment. In particular, a composition matter as an antitumor immunotherapy comprising a polyethyleneimine derivative as an immunoadjuvant, a chemotherapeutic drug, and optional components such as a microRNA, messenger RNA, plasmid DNA, siRNA, oligonucleotide, or a cyclic dinucleotide. A method for treating a subject with a cancer by administrating a therapeutic effective amount of a composition comprising a polyethyleneimine derivative and an antitumor agent to the subject in need of relief from said cancer is also within the scope of this disclosure.

Dependencies are inferred from the claim text.